Search research articles
Contact Us
Filters
Showing results (11-20 of 22) with videos related to
Page
of 3
Sort By:
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients
Matteo Bruno, Adriana Ionelia Apostol, Serena Maria Boccia, et al.
Cancer Management and Research
|
August 9, 2020
First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research
Federica Tomao, Serena Maria Boccia, Carolina Maria Sassu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 10, 2024
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients
Matteo Bruno, Adriana Ionelia Apostol, Serena Maria Boccia, et al.
International Journal of Clinical Oncology
|
June 30, 2025
Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis
Laura Vertechy, Raffaella Ergasti, Cristina Chiamenti, et al.
Gynecologic Oncology
|
May 14, 2019
Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Federica Tomao, Lucia Musacchio, Federica Di Mauro, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 8, 2026
Olaparib dose reduction in BRCA-mutated platinum-sensitive ovarian cancer recurrence: real-world data
Serena Maria Boccia, Matteo Bruno, Camilla Culcasi, et al.
International Journal of Clinical Oncology
|
November 4, 2025
Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy
Adriana Ionelia Apostol, Matteo Bruno, Carolina Maria Sassu, et al.
Critical Reviews in Oncology/Hematology
|
May 19, 2026
First-Line Immunotherapy With or Without PARP Inhibitors in Advanced Ovarian Cancer: A Meta-Analysis including Bevacizumab Use, Molecular Status, and PD-L1 Expression
Claudia Marchetti, Carolina Maria Sassu, Amedeo Cefaliello, et al.
Journal of Clinical Medicine
|
June 7, 2020
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
Lucia Musacchio, Serena Maria Boccia, Giuseppe Caruso, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 7, 2026
The impact of BRCA status on the efficacy of paclitaxel monotherapy in recurrent ovarian cancer
Giorgia Russo, Adriana Ionelia Apostol, Ilary Ruscito, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 22) with videos related to
Sort By:
Page
of 3
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 14, 2025
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients
Matteo Bruno, Adriana Ionelia Apostol, Serena Maria Boccia, et al.
Cancer Management and Research
|
August 9, 2020
First-Line Treatment with Olaparib for Early Stage BRCA-Positive Ovarian Cancer: May It Be Possible? Hypothesis Potentially Generating a Line of Research
Federica Tomao, Serena Maria Boccia, Carolina Maria Sassu, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
June 10, 2024
Effects of niraparib dose reduction on short-term outcomes in ovarian cancer patients
Matteo Bruno, Adriana Ionelia Apostol, Serena Maria Boccia, et al.
International Journal of Clinical Oncology
|
June 30, 2025
Platinum-rechallenge in epithelial ovarian cancer relapsing within 6 months after first-line treatment: a propensity score matching analysis
Laura Vertechy, Raffaella Ergasti, Cristina Chiamenti, et al.
Gynecologic Oncology
|
May 14, 2019
Is BRCA mutational status a predictor of platinum-based chemotherapy related hematologic toxicity in high-grade serous ovarian cancer patients?
Federica Tomao, Lucia Musacchio, Federica Di Mauro, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
January 8, 2026
Olaparib dose reduction in BRCA-mutated platinum-sensitive ovarian cancer recurrence: real-world data
Serena Maria Boccia, Matteo Bruno, Camilla Culcasi, et al.
International Journal of Clinical Oncology
|
November 4, 2025
Real-life observational study on niraparib in older patients with primary tubo-ovarian cancer: a focus on safety and efficacy
Adriana Ionelia Apostol, Matteo Bruno, Carolina Maria Sassu, et al.
Critical Reviews in Oncology/Hematology
|
May 19, 2026
First-Line Immunotherapy With or Without PARP Inhibitors in Advanced Ovarian Cancer: A Meta-Analysis including Bevacizumab Use, Molecular Status, and PD-L1 Expression
Claudia Marchetti, Carolina Maria Sassu, Amedeo Cefaliello, et al.
Journal of Clinical Medicine
|
June 7, 2020
Immune Checkpoint Inhibitors: A Promising Choice for Endometrial Cancer Patients?
Lucia Musacchio, Serena Maria Boccia, Giuseppe Caruso, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society
|
April 7, 2026
The impact of BRCA status on the efficacy of paclitaxel monotherapy in recurrent ovarian cancer
Giorgia Russo, Adriana Ionelia Apostol, Ilary Ruscito, et al.
Page
of 3